Sunyun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sunyun Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Sheng Yang
Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China
2 shared publications - Fan Yang
Department of Thoracic Surgery, Peking University People’s Hospital, Beijing, China
1 shared publication Fang Yuan
Department of Respiratory Medicine, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian, P.R. China
1 shared publicationNan Li
Department of Chinese Medicine, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian, P.R. China
1 shared publication- Qian Xu
Departments of Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, PR China
1 shared publication Qiong Luo
Department of Oncology, Fujian Medical University Union Hospital, Fujian Medical University Fuzhou, Fujian, P.R. China
1 shared publication
Latest Publications
- 1 February 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 23 (2) , 276-286
The Therapeutic Effects of Dihydroartemisinin on Cisplatin-Resistant Gastric Cancer Cells
Background: Dihydroartemisinin (DHA) exhibited anti-tumor effect in a variety of cancer cells, but its mechanism of action is unclear. Objective: To investigate the therapeutic effects of DHA on Cisplatin (DDP)-resistant gastric cancer cell strain SGC7901/DDP and the possible molecular mechanism. Methods: Cells were treated with DHA in a dose- and time-dependent manner, after which their proliferation, apoptosis, invasion, and migration abilities were evaluated. We further evaluated autophagy with mRFP-GFP-LC3 adenovirus transfection and transmission electron microscopy and also detected the expression levels of proteins (related to autophagy and apoptosis) via western blot. Meanwhile, the influence of DHA on cisplatin resistance was detected through a sensitization test and the evaluation of P-gp expression levels. Results: DHA effectively inhibited the proliferation, invasion, and migration of SGC7901/DDP cells and induced cell apoptosis which was accompanied by caspase-8/9/3 activation. Furthermore, exposure to DHA resulted in a pronounced increase in autophagy proteins, including Beclin-1 and LC3 II with PI3K/AKT/mTOR pathway inhibition. Additionally, enhancement of cisplatin sensitivity occurred in SGC7901/DDP cells treated with DHA, which was accompanied by P-gp downregulation. Conclusion: DHA exerts an anti-cancer effect on SGC7901/DDP cells and the mechanisms possibly include enhancement of autophagy via PI3K/AKT/mTOR inhibition, inducement of apoptosis through caspase-dependent and mitochondrial pathway, and enhancement of cisplatin sensitivity through P-gp inhibition.
- 1 February 2022
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 23 (2) , 276-286
The Therapeutic Effects of Dihydroartemisinin on Cisplatin-Resistant Gastric Cancer Cells
Background: Dihydroartemisinin (DHA) exhibited anti-tumor effect in a variety of cancer cells, but its mechanism of action is unclear. Objective: To investigate the therapeutic effects of DHA on Cisplatin (DDP)-resistant gastric cancer cell strain SGC7901/DDP and the possible molecular mechanism. Methods: Cells were treated with DHA in a dose- and time-dependent manner, after which their proliferation, apoptosis, invasion, and migration abilities were evaluated. We further evaluated autophagy with mRFP-GFP-LC3 adenovirus transfection and transmission electron microscopy and also detected the expression levels of proteins (related to autophagy and apoptosis) via western blot. Meanwhile, the influence of DHA on cisplatin resistance was detected through a sensitization test and the evaluation of P-gp expression levels. Results: DHA effectively inhibited the proliferation, invasion, and migration of SGC7901/DDP cells and induced cell apoptosis which was accompanied by caspase-8/9/3 activation. Furthermore, exposure to DHA resulted in a pronounced increase in autophagy proteins, including Beclin-1 and LC3 II with PI3K/AKT/mTOR pathway inhibition. Additionally, enhancement of cisplatin sensitivity occurred in SGC7901/DDP cells treated with DHA, which was accompanied by P-gp downregulation. Conclusion: DHA exerts an anti-cancer effect on SGC7901/DDP cells and the mechanisms possibly include enhancement of autophagy via PI3K/AKT/mTOR inhibition, inducement of apoptosis through caspase-dependent and mitochondrial pathway, and enhancement of cisplatin sensitivity through P-gp inhibition.
- Open Access
- 24 February 2021
- Published by Elsevier in Life Sciences
- Vol. 273, 119264
ADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation
- 24 February 2021
- Published by Elsevier in Life Sciences
- Vol. 273, 119264
Open AccessADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation